Zealand Pharma Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St

August 17, 2024

Zealand Pharma (CPH:ZEAL) Second Quarter 2024 Results

Key Financial Results

Revenue: kr.34.1m (up 228% from 2Q 2023).
Net loss: kr.292.8m (loss narrowed by 8.4% from 2Q 2023).
kr.4.67 loss per share (improved from kr.5.50 loss in 2Q 2023).

earnings-and-revenue-growth — CPSE:ZEAL Earnings and Revenue Growth August 17th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Zealand Pharma Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates significantly. Earnings per share (EPS) missed analyst estimates by 12%.

Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.

Performance of the market in Denmark.

The company's shares are up 6.9% from a week ago.

Risk Analysis

It is worth noting though that we have found 3 warning signs for Zealand Pharma that you need to take into consideration.

Valuation is complex, but we're here to simplify it.

Discover if Zealand Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.